Updated September 2026 · Educational trial summary

SURMOUNT and dual GIP/GLP-1: what the trials actually showed

Q: What did SURMOUNT-1 show for weight loss?

In SURMOUNT-1, adults with obesity or overweight plus a weight-related condition (without type 2 diabetes) receiving tirzepatide plus lifestyle intervention had substantially greater average percent weight reduction at 72 weeks than placebo, with higher doses associated with larger average reductions in published analyses (on the order of roughly 15% to about 21% depending on dose versus about 3% with placebo). Individual results vary.

Q: How does tirzepatide compare with semaglutide in SURMOUNT-5?

SURMOUNT-5 was an open-label Phase 3b trial comparing maximum tolerated tirzepatide with maximum tolerated semaglutide over 72 weeks in adults with obesity or overweight without diabetes. Published results reported greater average weight reduction with tirzepatide than with semaglutide. Cross-trial comparisons still require caution; talk with a clinician about individual care.

Q: Do trial averages guarantee personal results?

No. Clinical trial averages describe study populations under protocol conditions. They are not a promise of personal weight loss, cure, or absence of side effects.

The SURMOUNT program evaluates tirzepatide—a dual GIP and GLP-1 receptor agonist—primarily for chronic weight management in adults. This page summarizes published highlights for education. It is not medical advice, and trial averages are not a guarantee of personal outcomes.

FDA-approved U.S. brand names for tirzepatide include Zepbound® (weight management / related labeled uses) and Mounjaro® (type 2 diabetes). Compounded products are not FDA-approved and were not the investigational products in these brand-supported trials. This hub is independent of Eli Lilly.

Mechanism in one paragraph

Incretin hormones help regulate insulin and appetite after meals. GLP-1 receptor agonists act on GLP-1 pathways; tirzepatide is designed to engage both GIP and GLP-1 receptors. Dual agonism is a pharmacologic distinction studied in clinical development—it does not by itself prove superiority for every patient or endpoint.

SURMOUNT-1 (pivotal weight-management context)

SURMOUNT-1 enrolled adults with obesity, or overweight plus at least one weight-related comorbid condition, without type 2 diabetes. Participants received lifestyle intervention plus once-weekly tirzepatide (escalated to assigned maintenance doses) or placebo over 72 weeks in the primary treatment period.

Published analyses reported substantially greater average percent body-weight reduction with tirzepatide than with placebo. Manufacturer and peer-reviewed summaries have described approximate mean reductions on the order of ~15% at 5 mg, ~19–20% at 10 mg, and ~21% at 15 mg versus roughly ~3% with placebo at 72 weeks (exact estimands and figures depend on the publication’s analysis method). Higher proportions of tirzepatide-treated participants achieved categorical thresholds such as ≥10% or ≥20% weight reduction versus placebo.

Longer follow-up within the SURMOUNT-1 program (including participants with prediabetes followed for multiple years) has reported sustained weight reduction and lower rates of progression to type 2 diabetes versus placebo in published analyses—still under trial conditions, not everyday clinic guarantees.

Other SURMOUNT studies (short notes)

SURMOUNT-2: Adults with overweight/obesity and type 2 diabetes—weight and glycemic context differ from SURMOUNT-1.
SURMOUNT-3 / -4: Examined intensive lifestyle lead-in and withdrawal/maintenance designs—useful for understanding regain risk when medication stops.
SURMOUNT-5 (published 2025): Open-label comparison of maximum tolerated tirzepatide vs maximum tolerated semaglutide over 72 weeks in adults with obesity or overweight without diabetes. Published results reported greater average weight reduction with tirzepatide (on the order of ~20% vs ~14% in the primary published estimand summaries). Gastrointestinal adverse events were common in both groups.

How to read these numbers responsibly

Means describe groups; many individuals do better or worse.
Trials use structured dose escalation, lifestyle counseling, and close follow-up.
Stopping medication often leads to weight regain in withdrawal studies—obesity is typically managed as a chronic condition.
Safety findings (especially GI events during escalation) matter as much as efficacy averages—see side effects.
Results for FDA-approved tirzepatide products should not be assumed for compounded preparations.

FAQ

What did SURMOUNT-1 show for weight loss?

Average percent weight reduction with tirzepatide plus lifestyle was substantially greater than placebo at 72 weeks, with dose-related averages commonly summarized around ~15–21% versus ~3% placebo in published materials. Individual results vary.

How does tirzepatide compare with semaglutide in SURMOUNT-5?

Published SURMOUNT-5 results reported greater average weight reduction with maximum tolerated tirzepatide than with maximum tolerated semaglutide over 72 weeks. Discuss personal relevance with a clinician.

Do trial averages guarantee personal results?

No. They are not a cure claim or a promise of weight loss for any individual.

Sources to verify: peer-reviewed SURMOUNT publications (including NEJM reports), ClinicalTrials.gov identifiers for each study, and current FDA prescribing information for Zepbound® / Mounjaro®. Figures above are educational approximations—always check the primary paper for estimands.

Continue reading: Side effects & cautions · Compounded vs Zepbound®